RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
Registration Form
確認書
Japanese 8.0 KB
2025-11-12 08:30
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Registration Form
確認書
Japanese 7.9 KB
2025-06-20 03:49
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Governance Information
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Registration Form
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

QUINSTREET, INC Logo
AI-driven marketplaces connecting consumers to brands in finance & home services on a pay-per-result basis.
United States of America
QNST
Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978

Talk to a Data Expert

Have a question? We'll get back to you promptly.